{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.00","spread":"7.00","upperLimit":"8.53","value":"7.73"},{"groupId":"OG001","lowerLimit":"6.33","spread":"6.33","upperLimit":"7.73","value":"7.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"317"},{"groupId":"OG001","value":"320"}],"units":"Participants"}],"description":"Time to progression was measured from the start of the treatment to the time when the criteria for progression was met or death due to myeloma (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.","id":"OG000","title":"Vorinostat + Bortezomib"},{"description":"Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.","id":"OG001","title":"Placebo + Bortezomib"}],"paramType":"MEDIAN","populationDescription":"The analysis population includes all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline and at the end of each 21-day Cycle assessed up to 32 months (final study analysis)","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"Months"}